Physician profile
Usha Peri
NPI 1033100375
$13,086.35
in general payments reported to CMS, 2019-2025
31 companies · $6,711 in 2025
The $6,711 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $120 · 2021: $858 · 2022: $1,630 · 2023: $1,368 · 2024: $1,826 · 2025: $6,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,099 · Consulting Fee: $3,600 · Travel and Lodging: $1,204 · Education: $1.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.30 |
| Consulting Fee | $3,600.00 |
| Travel and Lodging | $1,204.36 |
| Education | $1.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $5,414.88 | 2019-2025 | |
| Amgen INC. | $958.56 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $952.28 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $927.32 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $849.79 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $521.04 | 2019-2025 | Rayaldee |
| Vifor Pharma, INC. | $359.56 | 2019-2023 | Veltassa |
| Mallinckrodt Hospital Products INC. | $358.00 | 2020-2025 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $357.10 | 2021-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $307.41 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $268.09 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $253.25 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $245.86 | 2022-2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.81 | 2019-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $208.24 | 2021-2025 | Lupkynis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $158.18 | 2022-2025 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $156.97 | 2025 | |
| Ardelyx, INC. | $135.67 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $70.52 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $60.41 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $57.50 | 2019-2021 | |
| Renalytix Ai, INC. | $41.56 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $32.79 | 2023-2024 | Jardiance |
| Cormedix INC. | $31.91 | 2024 | Defencath |
| Potrero Medical, INC. | $29.01 | 2021 | |
| Daiichi Sankyo INC. | $26.84 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $22.46 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $18.86 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.82 | 2019 | |
| Shire North American Group INC | $11.66 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Peri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.